# Arch Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arch-oncology

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Website: www.archoncology.com
- Total disclosed funding: $155M
- Latest round: Series C (Apr 27, 2021)
- Investors on record: 11

## About

Arch Oncology, Inc., based in the US, is dedicated to developing innovative therapeutic solutions for oncology, focusing on monoclonal antibodies designed to improve patient outcomes and minimize side effects of traditional cancer treatments.Founded in 2006 in Brisbane, US, Arch Oncology, Inc. develops monoclonal antibodies targeting cancer cells. The company secured USD 105.00 mn in Series C funding on April 27, 2021, led by investors including 3x5 Partners and Cowen Healthcare Investments. Julie Hambleton serves as CEO.Arch Oncology specializes in innovative therapeutic solutions for oncology, primarily developing monoclonal antibodies and biologics targeting cancer cells. Their products improve patient outcomes while reducing the side effects of traditional treatments, catering to healthcare providers, particularly oncologists and hospitals, across North America and Europe.Arch Oncology generates revenue through partnerships and collaborations with pharmaceutical firms and direct sales of their therapeutic products. Its transactions primarily involve B2B agreements, often structured around licensing arrangements for the use of its technologies in treatment regimens.With the recent Series C funding of USD 105.00 mn raised in April 2021, Arch Oncology plans to advance the clinical development of its anti-CD47 product candidate AO-176. The funding will facilitate progress in this area, supporting its strategy for addressing unmet medical needs in oncology.

## Funding rounds

- Series C, Apr 27, 2021, $105M — RiverVest Ventures Partners, Adage Capital Management, Roche Venture Fund, 503 Partners, Avego, Broadfin Capital, Eventide Asset Management, Point72 Asset Management, Lightchain Capital, Cowen Healthcare Investments, FMB Research
- Series B, Mar 25, 2019, $50M — RiverVest Ventures Partners, Roche Venture Fund, 503 Partners, Lightchain Capital

## Investors

- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series B, Series C
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series B, Series C
- 503 Partners (https://capitalatlas.ai/funds/503-partners) — Series B, Series C
- Lightchain Capital (https://capitalatlas.ai/funds/lightchain-capital) — Series B, Series C
- Adage Capital Management — Series C
- Avego (https://capitalatlas.ai/funds/avego) — Series C
- Broadfin Capital — Series C
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series C
- Point72 Asset Management — Series C
- Cowen Healthcare Investments — Series C
- FMB Research (https://capitalatlas.ai/funds/fmb-research) — Series C